# Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

> **NCT00264108** · — · COMPLETED · sponsor: **Janssen-Cilag B.V.** · enrollment: 492 (actual)

## Conditions studied

- Anemia
- Neoplasms

## Interventions

- **DRUG:** Darbepoetin alfa
- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00264108
- **Lead sponsor:** Janssen-Cilag B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 492 (ACTUAL)
- **Last updated:** 2014-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264108, "Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00264108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*